The meta-analysis used individual patient data (IPD) from four randomized controlled trials involving 1,731 women (1,036 allocated to DILAPAN-S, 695 to alternative cervical ripening methods).
A US, single-blind, randomised controlled trial of 80 women comparing DILAPAN-S with COOK balloon in outpatient cervical ripening. Full text link 10.1016/j.ajogmf.2025.101608
A single center, randomized trial of 296 women comparing DILAPAN-S with Foley balloon for inpatient cervical ripening.
A prospective randomised controlled trial of 174 women comparing DILAPAN-S with Foley balloon for outpatient cervical ripening.
A retrospective observational study accompanied by a prospective patient satisfaction survey. Conducted at two US hospitals within the same health system.
A prospective, dual-center pilot study comparing DILAPAN-S and COOK double balloon in outpatient cervical ripening. Conducted at two German university hospitals.
One of the earliest review articles on DILAPAN-S evaluating over 10 clinical trials from 2015-2022. It summarizes the evolving role of DILAPAN-S in labour induction, especially overviewing its effectiveness, safety, patient satisfaction and staff time savings compared to other cervical ripening methods.
First part of the presentation provides brief introduction of company MEDICEM, followed by overview of DILAPAN-S and IOL (induction of labour) market. Second part offers you an example of 2022 European communication strategy, incl. unmet needs and DILAPAN-S key benefits.
A health-economic model evaluating the cost and staff time of induction of labour with DILAPAN-S to Propess. Please feel free to download full study and executive summary with key outcomes.
A multi-center, randomised controlled trial of 307 women comparing DILAPAN-S to low dose 25 mcg oral misoprostole. Please feel free to download the full study and executive summary with key outcomes.
A multi-center, randomised controlled trial of 674 women comparing DILAPAN-S to Propess (dinoprostone vaginal insert). Please feel free to download the full study and executive summary with key outcomes.
The document overviews key take away messages of DILAPAN-S clinical trials and other publications related to induction of labour. Second part offers you examples of messages you can use to communicate DILAPAN-S benefits.
This website may contain general information relating to various medical conditions and their treatment. Such information is provided for informational purposes only and is not meant to be a substitute for the advice provided by a doctor or other qualified healthcare professional. You should not use the information contained herein for diagnosing a health or fitness problem or disease. You should always consult with a doctor or other healthcare professional. Featured products are not approved in every market, and approved labelling, indications and instructions may vary by country.
This website may contain general information relating to various medical conditions and their treatment. Such information is provided for informational purposes only and is not meant to be a substitute for the advice provided by a doctor or other qualified healthcare professional. You should not use the information contained herein for diagnosing a health or fitness problem or disease. You should always consult with a doctor or other healthcare professional. Featured products are not approved in every market, and approved labelling, indications and instructions may vary by country. Reference the Instructions for Use for a complete listing of indications, warnings and precautions.
© 2013−2024 Dilapan-S®
